Tumor News and Research

RSS

XPro1595 drug can protect vulnerable neurons, reduce motor deficits in Parkinson's model

An experimental anti-inflammatory drug can protect vulnerable neurons and reduce motor deficits in a rat model of Parkinson's disease, researchers at Emory University School of Medicine have shown.

26 Jul 2014

Experts at ABTA conference reveal possible causes, risk factors for brain tumors

Today, nearly 700,000 people in the U.S. are living with a brain tumor, and yet, when it comes to pinpointing causes or risk factors, scientists are still searching for answers.

25 Jul 2014

CCC study provides hope that SapC-DOPS could be used for metastatic brain cancer treatment

Over half of patients being seen in the clinic for a diagnosed brain tumor have metastatic cancer, which has no treatment and detrimental outcomes in most cases.

25 Jul 2014

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS).

25 Jul 2014

Natural products from plants can protect skin against gamma radiation during radiotherapy

Radiotherapy for cancer involves exposing the patient or their tumor more directly to ionizing radiation, such as gamma rays or X-rays.

25 Jul 2014

Neurosurgeons develop new technologies to perform highly complex brain surgery

In a milestone procedure, neurosurgeons at UC San Diego Health System have integrated advanced 3D imaging, computer simulation and next-generation surgical tools to perform a highly complex brain surgery through a small incision to remove deep-seated tumors.

25 Jul 2014

Clinical study aims to validate preventive treatment against tumor metastasis

Metastasis, the strategy adopted by tumor cells to transform into an aggressive form of cancer, are often associated with a gloomy prognosis. Managing to block the metastasis or, even better, prevent their formation would be a giant step towards the fight against cancer.

25 Jul 2014

Kinex receives FDA approval to begin Phase I study of KX2-391 Ointment for actinic keratosis

Kinex Pharmaceuticals announced the receipt of an allowance by the US FDA for the Company's KX2-391 Ointment for the commencement of a Phase I clinical study in actinic keratosis. This is the Company's third IND to be allowed by the US FDA in the past 12 months.

25 Jul 2014

Research suggests effective role for natural steroid hormones in treating breast cancer

A new study supports a growing body of research suggesting a safe and effective role for natural steroid hormones in treating postmenopausal breast cancer, with fewer detrimental side effects and improved health profile than with standard anti-hormone therapies.

24 Jul 2014

Study identifies three genetic changes linked to increased risk of breast cancer in East Asian women

A new study in East Asian women has identified three genetic changes linked to an increased risk of breast cancer. The research, led by Vanderbilt University investigators, was published online July 20 in Nature Genetics.

24 Jul 2014

Capsazepine shows dramatic tumor shrinkage without damaging surrounding tissues

Mouse models of human oral cancer treated with an agent called capsazepine showed dramatic tumor shrinkage without damage to surrounding tissues, researchers from the School of Dentistry and School of Medicine at The University of Texas Health Science Center at San Antonio found.

24 Jul 2014

Cedars-Sinai investigators developing novel treatment for locally advanced pancreatic cancer

Investigators at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute are developing a novel, multistep investigational treatment for one of the most complex and difficult-to-treat forms of the disease, locally advanced pancreatic cancer.

23 Jul 2014

Vanderbilt-led research team identifies protein "signatures" that drive colorectal cancer

A Vanderbilt University-led research team has identified protein "signatures" of genetic mutations that drive colorectal cancer, the nation's second leading cause of cancer deaths after lung cancer.

23 Jul 2014

New molecules and biopharmaceuticals enhance patient's immune response against tumors

Researchers at the University of Arkansas have been awarded $1.5 million from the National Cancer Institute at the National Institutes of Health to develop new molecules and biopharmaceuticals that enhance a patient's immune response against tumors.

22 Jul 2014

Study shows inactivation of p53 protein promotes cancer progression

Researchers at the Bellvitge Biomedical Research Institute (IDIBELL) and the University of Barcelona have discovered the interaction between HERC2 proteins with another protein called p53 that is inactivated in more than half of human tumors.

22 Jul 2014

Study confirms effectiveness of EKF PointMan technology for isolating low-level DNA mutations in blood

EKF, announces that the latest results from its collaboration with the Institute of Life Sciences at the University of Swansea, UK.

From EKF Diagnostics 22 Jul 2014

Varian receives 510(k) clearance from FDA for Calypso soft tissue Beacon transponder

Varian Medical Systems today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a Calypso® soft tissue Beacon® transponder that can help enhance the precision of radiotherapy and radiosurgery treatments for cancer.

21 Jul 2014

New York State DOH grants RPCI approval to begin genomic testing of cancer patients

The New York State Department of Health (DOH) has granted Roswell Park Cancer Institute (RPCI) approval to begin genomic testing of cancer patients using its OmniSeq TargetTM advanced molecular diagnostic laboratory test.

21 Jul 2014

CFDA approves CASI's ENMD-2076 Phase II trial in triple-negative breast cancer patients

CASI Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and other diseases, announced today that China's Food and Drug Administration has approved the Company's application to conduct a Phase II clinical trial in triple-negative breast cancer (TNBC) patients in China for its proprietary drug candidate, ENMD-2076.

21 Jul 2014

A personalized approach for patients with ccRCC-related mutations

In an analysis of small molecules called metabolites used by the body to make fuel in normal and cancerous cells in human kidney tissue, a research team from the Perelman School of Medicine at the University of Pennsylvania identified an enzyme key to applying the brakes on tumor growth.

21 Jul 2014

Tumor News and Research

XPro1595 drug can protect vulnerable neurons, reduce motor deficits in Parkinson's model

Experts at ABTA conference reveal possible causes, risk factors for brain tumors

CCC study provides hope that SapC-DOPS could be used for metastatic brain cancer treatment

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Natural products from plants can protect skin against gamma radiation during radiotherapy

Neurosurgeons develop new technologies to perform highly complex brain surgery

Clinical study aims to validate preventive treatment against tumor metastasis

Kinex receives FDA approval to begin Phase I study of KX2-391 Ointment for actinic keratosis

Research suggests effective role for natural steroid hormones in treating breast cancer

Study identifies three genetic changes linked to increased risk of breast cancer in East Asian women

Capsazepine shows dramatic tumor shrinkage without damaging surrounding tissues

Cedars-Sinai investigators developing novel treatment for locally advanced pancreatic cancer

Vanderbilt-led research team identifies protein "signatures" that drive colorectal cancer

New molecules and biopharmaceuticals enhance patient's immune response against tumors

Study shows inactivation of p53 protein promotes cancer progression

Study confirms effectiveness of EKF PointMan technology for isolating low-level DNA mutations in blood

Varian receives 510(k) clearance from FDA for Calypso soft tissue Beacon transponder

New York State DOH grants RPCI approval to begin genomic testing of cancer patients

CFDA approves CASI's ENMD-2076 Phase II trial in triple-negative breast cancer patients

A personalized approach for patients with ccRCC-related mutations

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News